Hepatocellular Carcinoma Drugs Market Trends, Major Drivers, Opportunities And Forecast 2024-2033

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033.

The Business Research Company offers in-depth market insights through Hepatocellular Carcinoma Drugs Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The hepatocellular carcinoma drugs market size has grown strongly in recent years. It will grow from $1.07 billion in 2023 to $1.17 billion in 2024 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to increased disease incidence, advancements in cancer research, global healthcare infrastructure improvement, regulatory approvals, awareness and early diagnosis initiatives.

The hepatocellular carcinoma drugs market size is expected to see strong growth in the next few years. It will grow to $1.62 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to targeted therapies advancements, increasing geriatric population, healthcare personalization trends, global expansion of treatment access. Major trends in the forecast period include access to innovative therapies, patient-centric care, regulatory advancements, drug resistance mitigation strategies, collaborative research initiatives.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=10809&type=smp

Market Segmentation:
The hepatocellular carcinoma drugs market covered in this report is segmented -
1) By Type: Brachytherapy, Chemotherapy
2) By Drug Class: PD-1/PD-L1 Inhibitors, Tyrosine Kinase Inhibitors
3) By End User: Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgical Centers

Major Driver - Rising Occurrence Of Hepatocellular Carcinoma Fuels Growth In The Hepatocellular Carcinoma Drug Market
The rise in the occurrence of hepatocellular carcinoma is expected to propel the growth of the hepatocellular carcinoma drug market over the coming years. Hepatocellular carcinoma (HCC) is a primary malignant disease of the liver and the most common form of liver cancer. Hepatocellular carcinoma starts with the main type of liver cells called hepatocyte cells. Most cases of HCC result from infection with hepatitis B or C, or cirrhosis. As the occurrence of hepatocellular carcinoma continuing to rise, it leads to an increased demand for effective hepatocellular carcinoma drugs to treat the disease. For instance, in 2023, according to the report published by the American Cancer Society, Inc, a US-based nationwide voluntary health organization dedicated to eliminating cancer, estimated new cases of liver cancer in females diagnosed in the United States increased from 12,660 in 2022 to 13,230 in 2023. Therefore, the rise in the occurrence of hepatocellular carcinoma is driving the growth of the hepatocellular carcinoma drug market.

Competitive Landscape:
Major companies operating in the hepatocellular carcinoma drugs market report are AbbVie Inc., Amgen Inc., Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Co.Ltd., Eli Lilly and Company, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, Gilead Sciences Inc., GlaxoSmithKline, Exelixis Inc., Ipsen Pharma Biotech SAS, AstraZeneca plc, BeiGene Ltd., Ono Pharmaceutical Co. Ltd., Roche Holdings AG, Sanofi S.A., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., TTY Biopharm Company Limited, Hengrui Medicine Co. Ltd., CSPC Pharmaceutical Group Limited, Hutchison China MediTech Limited, Jiangsu Hengrui Medicine Co. Ltd.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/hepatocellular-carcinoma-drugs-global-market-report

Top Trend - Laboratory-Produced Molecule In The Hepatocellular Carcinoma Drugs Market
Major companies operating in the hepatocellular carcinoma drugs market are developing laboratory-produced molecule such as monoclonal antibodies (mAb) to meet larger customer bases, more sales, and increase revenue. A monoclonal antibody (mAb) is a laboratory-produced molecule that is engineered to mimic the immune system's ability to fight off harmful pathogens such as bacteria or viruses. For instance, in October 2022, AstraZeneca Plc, a UK-based pharmaceutical and biotechnology company, announced the US Food and Drug Administration (FDA) approval for Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) Indicated for adult patients with hepatocellular carcinoma (HCC). Imfinzi (durvalumab) is a distinctive human monoclonal antibody that effectively binds to the PD-L1 protein. By doing so, it hinders the interaction between PD-L1 and the PD-1 and CD80 proteins. This action disrupts the tumor's evasion of the immune system, releasing the inhibition of immune responses. As for Imjudo (tremelimumab), it stands out as a human monoclonal antibody designed to specifically target the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Imjudo works by blocking CTLA-4 activity, thereby promoting T-cell activation, priming the immune response against cancer, and fostering the death of cancer cells.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Hepatocellular Carcinoma Drugs Market Characteristics
3. Hepatocellular Carcinoma Drugs Market Trends And Strategies
4. Hepatocellular Carcinoma Drugs Market - Macro Economic Scenario
5. Hepatocellular Carcinoma Drugs Market Size And Growth
…..
27. Hepatocellular Carcinoma Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.